Novel Approach for Evaluating and Treating Advanced Breast Cancer Patients Whose Tumors Overexpress HER-2/neu

摘要

The goal of this research is to develop stable radioimmunoconjugates (RICs) of an anti-HER 2/neu antibodies (MoAbs) for imaging and therapy in an animal model bearing human breast tumors. Pharmacy-grade Herceptin and an anti- HER2/neu antibody were conjugated with a DTPA linker. InCl(3)111 and YCl(3)90 were labeled to MoAb-CHX-A-DTPA according to the procedure of Clarke et al. (Cancer Res 60: 4804, 2000). Binding capacity of RICs was tested with human cancer cell lines MCF-7, HCC-1954, BT-474 and SKBR-3.